Key Points
- Director Nadja West sold 2,178 Tenet shares on Dec. 15 at an average price of $197.47 for a total of $430,089.66, reducing her stake by 7.10% to 28,480 shares valued at about $5.62 million.
- Tenet recently reported a quarterly EPS beat ($3.70 vs. $3.33 est.) and set FY2025 guidance of 15.93–16.26 EPS, while analysts maintain a "Moderate Buy" consensus with a $231.81 average price target.
Tenet Healthcare Corporation (NYSE:THC - Get Free Report) Director Nadja West sold 2,178 shares of the firm's stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $197.47, for a total value of $430,089.66. Following the completion of the sale, the director directly owned 28,480 shares in the company, valued at $5,623,945.60. This trade represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Tenet Healthcare Price Performance
Shares of THC stock traded up $2.12 on Thursday, reaching $197.14. The company had a trading volume of 11,010 shares, compared to its average volume of 1,374,247. The stock has a market capitalization of $17.33 billion, a PE ratio of 13.51, a price-to-earnings-growth ratio of 0.86 and a beta of 1.44. The company has a quick ratio of 1.64, a current ratio of 1.71 and a debt-to-equity ratio of 2.27. The business's 50-day moving average is $202.87 and its 200 day moving average is $186.01. Tenet Healthcare Corporation has a one year low of $109.82 and a one year high of $222.82.
Tenet Healthcare (NYSE:THC - Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The company reported $3.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.33 by $0.37. The business had revenue of $5.29 billion during the quarter, compared to analysts' expectations of $5.26 billion. Tenet Healthcare had a net margin of 6.49% and a return on equity of 25.11%. The firm's quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.93 EPS. Tenet Healthcare has set its FY 2025 guidance at 15.930-16.26 EPS. Equities research analysts forecast that Tenet Healthcare Corporation will post 12.24 EPS for the current fiscal year.
Hedge Funds Weigh In On Tenet Healthcare
Institutional investors have recently added to or reduced their stakes in the business. AlphaQuest LLC lifted its position in shares of Tenet Healthcare by 230.8% during the 2nd quarter. AlphaQuest LLC now owns 1,763 shares of the company's stock valued at $310,000 after buying an additional 1,230 shares during the last quarter. 111 Capital bought a new position in Tenet Healthcare during the second quarter worth about $244,000. Cerity Partners LLC raised its position in shares of Tenet Healthcare by 10.4% in the second quarter. Cerity Partners LLC now owns 120,623 shares of the company's stock valued at $21,230,000 after purchasing an additional 11,395 shares during the period. Royal Bank of Canada lifted its stake in shares of Tenet Healthcare by 34.0% during the 1st quarter. Royal Bank of Canada now owns 119,349 shares of the company's stock valued at $16,052,000 after buying an additional 30,281 shares in the last quarter. Finally, Leith Wheeler Investment Counsel Ltd. grew its stake in Tenet Healthcare by 22.2% in the 2nd quarter. Leith Wheeler Investment Counsel Ltd. now owns 82,813 shares of the company's stock valued at $14,575,000 after buying an additional 15,019 shares in the last quarter. 95.44% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on the company. Bank of America boosted their price target on Tenet Healthcare from $205.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, September 10th. Royal Bank Of Canada raised their target price on Tenet Healthcare from $230.00 to $252.00 and gave the stock an "outperform" rating in a research report on Thursday, October 30th. JPMorgan Chase & Co. increased their price target on Tenet Healthcare from $200.00 to $230.00 and gave the company an "overweight" rating in a research note on Thursday, November 13th. Guggenheim lifted their price objective on Tenet Healthcare from $238.00 to $257.00 and gave the stock a "buy" rating in a research note on Tuesday, December 2nd. Finally, Mizuho increased their target price on shares of Tenet Healthcare from $194.00 to $225.00 and gave the company an "outperform" rating in a research report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $231.81.
View Our Latest Analysis on Tenet Healthcare
Tenet Healthcare Company Profile
(
Get Free Report)
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
